Research graph
References from MuSK agonistic antibody has therapeutic potential for MuSK antibody-positive myasthenia gravis. Local targets link to admitted publications; unresolved targets remain external evidence.
The neuromuscular junction in health and disease: molecular mechanisms governing synaptic formation and homeostasis
10.3389/fnmol.2020.610964 · 2020 · External reference
Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies
10.1038/85520 · 2001 · External reference
Muscle-specific kinase myasthenia gravis
10.3389/fimmu.2020.00707 · 2020 · External reference
Understanding the burden of refractory myasthenia gravis
10.1177/1756286419832242 · 2019 · External reference
Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis
10.1136/jnnp-2022-330519 · 2023 · External reference
Lrp4 is a receptor for agrin and forms a complex with MuSK
10.1016/j.cell.2008.10.002 · 2008 · External reference
Agrin binds to the N-terminal region of Lrp4 protein and stimulates association between Lrp4 and the first immunoglobulin-like domain in muscle-specific kinase (MuSK)
10.1074/jbc.m111.279307 · 2011 · External reference
LRP4 serves as a coreceptor of agrin
10.1016/j.neuron.2008.10.006 · 2008 · External reference
Structural insights into the assembly of the agrin/LRP4/MuSK signaling complex
10.1073/pnas.2300453120 · 2023 · External reference
Structural basis of agrin-LRP4-MuSK signaling
10.1101/gad.180885.111 · 2012 · External reference
MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4
10.1073/pnas.1313944110 · 2013 · External reference
Neuromuscular junctions as key contributors and therapeutic targets in spinal muscular atrophy
10.3389/fnana.2016.00006 · 2016 · External reference
AAV9-DOK7 gene therapy reduces disease severity in Smn(2B/-) SMA model mice
10.1016/j.bbrc.2020.07.031 · 2020 · External reference
Neuromuscular disease. DOK7 gene therapy benefits mouse models of diseases characterized by defects in the neuromuscular junction
10.1126/science.1250744 · 2014 · External reference
Activation of muscle-specific kinase (MuSK) reduces neuromuscular defects in the Delta7 mouse model of spinal muscular atrophy (SMA)
10.3390/ijms22158015 · 2021 · External reference
Neuromuscular junction changes in a mouse model of Charcot-Marie-Tooth disease type 4C
10.3390/ijms19124072 · 2018 · External reference
Increasing MuSK activity delays denervation and improves motor function in ALS mice
10.1016/j.celrep.2012.08.004 · 2012 · External reference
Mechanism of disease and therapeutic rescue of Dok7 congenital myasthenia
10.1038/s41586-021-03672-3 · 2021 · External reference
ARGX-119 is an agonist antibody for human MuSK that reverses disease relapse in a mouse model of congenital myasthenic syndrome
10.1126/scitranslmed.ado7189 · 2024 · External reference
Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models
10.1016/j.isci.2024.111684 · 2025 · External reference
Preserving neuromuscular synapses in ALS by stimulating MuSK with a therapeutic agonist antibody
10.7554/elife.34375 · 2018 · External reference
Agonist antibody to MuSK protects mice from MuSK myasthenia gravis
10.1073/pnas.2408324121 · 2024 · External reference
Gene-specific response to muscle specific kinase agonist antibody in the treatment of congenital myasthenic syndromes
10.1093/braincomms/fcag115 · 2026 · External reference
Novel Antibody Exerts Antitumor Effect through Downregulation of CD147 and Activation of Multiple Stress Signals
10.1155/2022/3552793 · 2022 · External reference
Use of human germline genes in a CDR homology-based approach to antibody humanization
10.1016/j.ymeth.2005.01.004 · 2005 · External reference
Human Fc gamma RI and Fc gamma RII interact with distinct but overlapping sites on human IgG
10.4049/jimmunol.147.8.2657 · 1991 · External reference
Development and characterization of agonistic antibodies targeting the Ig-like 1 domain of MuSK
10.1038/s41598-023-32641-1 · 2023 · External reference
Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis
10.1016/j.ajpath.2011.10.031 · 2012 · External reference
Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects
10.1016/j.expneurol.2012.01.025 · 2012 · External reference
Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis
10.1073/pnas.2020635118 · 2021 · External reference
Wnt proteins regulate acetylcholine receptor clustering in muscle cells
10.1186/1756-6606-5-7 · 2012 · External reference
Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human
10.4161/mabs.23684 · 2013 · External reference
Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies
10.1080/19420862.2022.2085535 · 2022 · External reference
Laboratory investigation of hybrid IgG4 k/lambda in MuSK positive myasthenia gravis
10.3390/ijms22179142 · 2021 · External reference
Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients
10.1172/jci.insight.127167 · 2019 · External reference
IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients
10.1016/j.jaut.2016.11.005 · 2017 · External reference
Affinity maturation is required for pathogenic monovalent IgG4 autoantibody development in myasthenia gravis
10.1084/jem.20200513 · 2020 · External reference
IgG1-3 MuSK antibodies inhibit AChR cluster formation, restored by SHP2 inhibitor, despite normal MuSK, DOK7, or AChR subunit phosphorylation
10.1212/nxi.0000000000200147 · 2023 · External reference
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
10.1016/s1474-4422(17)30369-1 · 2017 · External reference
Long-term safety and efficacy of eculizumab in generalized myasthenia gravis
10.1002/mus.26447 · 2019 · External reference
Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis
10.4049/jimmunol.179.12.8562 · 2007 · External reference
Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis
10.1007/s00415-014-7532-3 · 2015 · External reference
Efficacy and safety of low-dose rituximab in Anti-MuSK myasthenia gravis patients: a retrospective study
10.2147/ndt.s358851 · 2022 · External reference
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
10.1016/s1474-4422(21)00159-9 · 2021 · External reference
Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis
10.1016/j.expneurol.2019.03.001 · 2019 · External reference
Effectiveness and safety of rituximab for refractory myasthenia gravis: a systematic review and single-arm meta-analysis
10.3389/fneur.2021.736190 · 2021 · External reference
A real-world pharmacovigilance study of efgartigimod alfa in the FDA adverse event reporting system database
2025 · External reference
Neuromuscular junction transmission failure in aging and sarcopenia: the nexus of the neurological and muscular systems
10.1016/j.arr.2023.101966 · 2023 · External reference
Sarcoglycan alpha mitigates neuromuscular junction decline in aged mice by stabilizing LRP4
10.1523/jneurosci.0860-18.2018 · 2018 · External reference
DOK7 gene therapy enhances neuromuscular junction innervation and motor function in aged mice
10.1016/j.isci.2020.101385 · 2020 · External reference
IgG4 autoantibodies in organ-specific autoimmunopathies: reviewing class switching, antibody-producing cells, and specific immunotherapies
10.3389/fimmu.2022.834342 · 2022 · External reference
